

Microba receives approval of two R&D Tax Incentive Advanced Overseas Findings

- Microba has received two separate positive Overseas Advanced Findings from AusIndustry related to its Inflammatory Bowel Disease and Autoimmune Disease therapeutic programs under the R&D Tax Incentive
- The findings cover eligible expenditure up to \$13,400,000 and may result in R&D Tax Incentive cash rebates to the company of up to \$5,829,000 across financial years 2022, 2023 and 2024

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that it has received approval from AusIndustry for two separate applications for Advanced Overseas Findings for research and development expenditure associated with its Inflammatory Bowel Disease (IBD) and Autoimmune Disease therapeutic programs. The two Advanced Overseas Findings cover total overseas expenditure of up to \$13,400,000 and may result in R&D Tax Incentive cash rebates to the Company of up to \$5,829,000.

The first Advanced Overseas Finding relates to Microba's engagement with Bacthera, located in Switzerland, for the manufacturing of Microba's MAP 315 lead drug candidate for the Company's planned Phase I clinical trial for its IBD program.

The second Advanced Overseas Finding relates to Microba's engagement with Ginkgo Bioworks (NYSE: DNA), located in the United States, to perform high throughput screening of bacterial strains for its Autoimmune Disease program targeting three autoimmune disorders (lupus, psoriatic arthritis and autoimmune liver diseases).

The findings cover financial years 2022, 2023 and 2024 and mean that these eligible overseas research and development expenditures related to Microba's IBD and Autoimmune programs, in addition to eligible Australian expenditure, will be subject to a 43.5% cash rebate under the Australian Federal Government's R&D Tax Incentive Program.

Microba's Chief Executive Officer, Dr. Luke Reid, said, "We sincerely appreciate this support from the Australian Government. We believe that Microba's novel therapeutics can make a positive impact on Australian lives in the future, and the R&D Tax Incentive Program is supporting Microba to make this a reality"

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.